Cabaletta Bio (NASDAQ:CABA) is a clinical-stage biotechnology company focused on the discovery and development of precision T cell therapies for patients with severe autoimmune and chronic inflammatory diseases. Utilizing its proprietary chimeric autoantibody receptor T cell (CAAR-T) platform, Cabaletta engineers antigen-specific T cells designed to selectively target and eliminate pathogenic, autoreactive B cells while sparing protective immune cells. The company’s lead candidate, DSG3-CAART, is currently being evaluated in patients with mucocutaneous pemphigus vulgaris, a rare and potentially life-threatening skin disorder driven by autoantibodies against desmoglein 3.
In addition to its lead program, Cabaletta is advancing a pipeline of next-generation CAAR-T and related T cell therapies for other antibody-mediated conditions including muscle-specific kinase (MuSK) myasthenia gravis and other severe autoimmunity targets. Preclinical studies indicate that the firm’s modular platform may be readily adapted to different disease-relevant antigens, offering the potential for a broad range of applications across immunological diseases. Cabaletta also maintains strategic collaborations and research partnerships to support translational studies and expand its pipeline.
Founded in 2017 as a spin-out from academic research at the University of Pennsylvania, Cabaletta Bio is headquartered in Philadelphia, Pennsylvania. The company operates a research and development hub that integrates cell engineering, translational immunology, and clinical operations. With an emphasis on rigorous scientific validation, Cabaletta has secured necessary regulatory clearances to initiate multiple early-stage clinical trials in the United States and plans to expand its trial network globally.
Led by a seasoned management team with extensive experience in cell therapy, immunology and late-stage clinical development, Cabaletta is guided by CEO David P. Lockhart, Ph.D., whose prior roles include senior leadership positions at major biotechnology and pharmaceutical companies. Supported by a board of directors and advisors comprising both industry veterans and academic experts, the company is positioned to advance its innovative T cell therapies toward potential registration and commercialization.
